BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

948 related articles for article (PubMed ID: 27890259)

  • 1. How important is NK alloreactivity and KIR in allogeneic transplantation?
    Shaffer BC; Hsu KC
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
    Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.
    Bishara A; De Santis D; Witt CC; Brautbar C; Christiansen FT; Or R; Nagler A; Slavin S
    Tissue Antigens; 2004 Mar; 63(3):204-11. PubMed ID: 14989709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic polymorphism and allogeneic hematopoietic transplantation outcome.
    Mullighan CG; Petersdorf EW
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):19-27. PubMed ID: 16399580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation.
    Hadjis AD; McCurdy SR
    Front Immunol; 2024; 15():1358668. PubMed ID: 38817602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
    Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
    J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactive natural killer cells in mismatched hematopoietic stem cell transplantation.
    Ruggeri L; Capanni M; Mancusi A; Urbani E; Perruccio K; Burchielli E; Tosti A; Topini F; Aversa F; Martelli MF; Velardi A
    Blood Cells Mol Dis; 2004; 33(3):216-21. PubMed ID: 15528134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity.
    Shaffer BC; Hsu KC
    Semin Hematol; 2020 Oct; 57(4):167-174. PubMed ID: 33256909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.
    Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T
    Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.
    Cooley S; Trachtenberg E; Bergemann TL; Saeteurn K; Klein J; Le CT; Marsh SG; Guethlein LA; Parham P; Miller JS; Weisdorf DJ
    Blood; 2009 Jan; 113(3):726-32. PubMed ID: 18945962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Natural Killer Cell-Associated Factors on Acute Leukemia Outcomes after Haploidentical Hematopoietic Stem Cell Transplantation with αβ T Cell Depletion in a Pediatric Cohort.
    Glushkova S; Shelikhova L; Voronin K; Pershin D; Vedmedskaya V; Muzalevskii Y; Kazachenok A; Kurnikova E; Radygina S; Ilushina M; Khismatullina R; Maschan A; Maschan M
    Transplant Cell Ther; 2024 Apr; 30(4):435.e1-435.e12. PubMed ID: 38278183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
    Chang YJ; Zhao XY; Huang XJ
    Front Immunol; 2018; 9():3041. PubMed ID: 30619371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of natural killer cell killer Ig-like receptor alloreactivity on the outcome of bone marrow stem cell transplantation for severe combined immunodeficiency (SCID).
    Keller MD; Chen DF; Condron SA; Liu N; Reinsmoen NL; Buckley RH
    J Clin Immunol; 2007 Jan; 27(1):109-16. PubMed ID: 17191149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of NK cells in allogeneic hematopoietic stem cell transplantation--review].
    Li XH; Gao CJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):845-8. PubMed ID: 16928336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Choi Y; Min WS; Kim TG; Cho BS; Kim SY; Eom KS; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim CC
    Transplantation; 2007 Nov; 84(9):1082-91. PubMed ID: 17998861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Ruggeri L; Capanni M; Urbani E; Perruccio K; Shlomchik WD; Tosti A; Posati S; Rogaia D; Frassoni F; Aversa F; Martelli MF; Velardi A
    Science; 2002 Mar; 295(5562):2097-100. PubMed ID: 11896281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.